Supplemental material
Leukemia & Lymphoma
Volume 61, 2020 - Issue 11
Original Articles
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
Armon Azizia Department of Medicine, Division of Hematology, Cancer Institute, Stanford University, Stanford, CA, USA
https://orcid.org/0000-0002-1353-2060View further author information
https://orcid.org/0000-0002-1353-2060View further author information, , , Shyam A. Patelb Department of Medicine, Division of Hematology-Oncology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USAhttps://orcid.org/0000-0002-8208-1902View further author information
https://orcid.org/0000-0002-8208-1902View further author information, William Shomalia Department of Medicine, Division of Hematology, Cancer Institute, Stanford University, Stanford, CA, USAhttps://orcid.org/0000-0001-6500-350XView further author information
https://orcid.org/0000-0001-6500-350XView further author information, , , , , , Ravindra Majetia Department of Medicine, Division of Hematology, Cancer Institute, Stanford University, Stanford, CA, USAhttps://orcid.org/0000-0002-5814-0984View further author information
https://orcid.org/0000-0002-5814-0984View further author information & Tian Zhanga Department of Medicine, Division of Hematology, Cancer Institute, Stanford University, Stanford, CA, USACorrespondence[email protected]
https://orcid.org/0000-0002-6274-0763View further author information
https://orcid.org/0000-0002-6274-0763View further author information show all